Sha. Davies et al., MODULATION OF LIPID POLYMORPHISM BY THE FELINE LEUKEMIA-VIRUS FUSION PEPTIDE - IMPLICATIONS FOR THE FUSION MECHANISM, Biochemistry, 37(16), 1998, pp. 5720-5729
The structural effects of the fusion peptide of feline leukemia virus
(FeLV) on lipid polymorphism were studied, using differential scanning
calorimetry (DSC, P-31 nuclear magnetic resonance (NMR), and time-res
olved X-ray diffraction. This peptide lowers the bilayer to inverted h
exagonal phase transition temperature, T-H, Of dipalmitoleoylphosphati
dylethanolamine (DiPoPE) at peptide mole fractions of up to 1.5 x 10(-
3) at pH 5.0 and at pH 7.4. The temperature at which isotropic P-31 NM
R signals for monomethyldioleoylphosphatidylethanolamine (MeDOPE) firs
t occurred is lowered by the FeLV peptide. The amount of isotropic sig
nal seen at 40 degrees C is directly correlated to the peptide:lipid m
olar ratio. In the peptide-containing samples, more lipid remains in t
he isotropic state over the whole recorded temperature range. Isotropi
c P-31 NMR signals were observed for DiPoPE in the presence of the FeL
V peptide for the entire recorded temperature range of 35-50 degrees C
, while pure DiPoPE showed no significant amount of isotropic signal.
X-ray studies of DiPoPE show the formation of a new lipid phase with p
eptide, which is not seen in the pure Lipid samples. Disordering of th
e L-alpha phase is evidenced by broadening of the diffraction peaks, a
nd the hexagonal cell parameter is decreased with peptide present. Our
results suggest that the FeLV peptide is increasing the negative curv
ature of the lipid system, which is thought to be crucial to the forma
tion of highly bent, high-energy structural fusion intermediates, such
as the ''stalk'' model. Fusion activity for this putative fusogenic p
eptide was also demonstrated, using a resonance energy transfer (RET)
Lipid mixing assay. To our knowledge, this work provides the first pub
lished experimental evidence of both fusogenic activity and effects on
Lipid polymorphism for the FeLV fusion peptide.